CurrentRheuma
Get Weekly

CurrentRheuma coverage · page 12 of 15

Annals of the Rheumatic Diseases

Briefs 441–480 of 596 CurrentRheuma has covered from this journal, newest publication first

Latest from Annals of the Rheumatic Diseases

All coverage, newest first

  1. Ann Rheum Dis

    Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis

    Secondary analysisRA

  2. Ann Rheum Dis

    Male patients with inflammatory joint diseases are less likely than controls to be childless: results from a Norwegian population-based cohort study of 10 865 patients

    Cohort studyAcross diseases

  3. Ann Rheum Dis

    Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study

    Cohort studySpondyloarthritis & PsA

  4. Ann Rheum Dis

    Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression

    Cohort studyLupus & APS

  5. Ann Rheum Dis

    Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone

    Randomized controlled trialOsteoporosis

  6. Ann Rheum Dis

    Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

    Randomized controlled trialLupus & APS

  7. Ann Rheum Dis

    Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023

    Guideline or statementAcross diseases

  8. Ann Rheum Dis

    CD_99 G1 neutrophils modulate osteogenic differentiation of mesenchymal stem cells in the pathological process of ankylosing spondylitis

    Mechanistic studySpondyloarthritis & PsA

  9. Ann Rheum Dis

    Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis

    Mechanistic studyRA

  10. Ann Rheum Dis

    In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation

    Cross-sectional studyRA

  11. Ann Rheum Dis

    Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial

    Randomized controlled trialSjögren's & overlap

  12. Ann Rheum Dis

    Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcome

    Mechanistic studyRA

  13. Ann Rheum Dis

    Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial

    Randomized controlled trialVasculitis & PMR

  14. Ann Rheum Dis

    Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways

    Mechanistic studyVasculitis & PMR

  15. Ann Rheum Dis

    Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry

    Cohort studyAutoinflammatory & rare

  16. Ann Rheum Dis

    Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies

    Cohort studyRA

  17. Ann Rheum Dis

    Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica

    Cohort studyVasculitis & PMR

  18. Ann Rheum Dis

    Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO)

    Cross-sectional studyAcross diseases

  19. Ann Rheum Dis

    Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies

    Meta-analysisRA

  20. Ann Rheum Dis

    Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

    Randomized controlled trialSpondyloarthritis & PsA

  21. Ann Rheum Dis

    Definition of rheumatoid arthritis flare based on SDAI and CDAI

    Diagnostic or prognostic studyRA

  22. Ann Rheum Dis

    Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping

    Cross-sectional studyAcross diseases

  23. Ann Rheum Dis

    Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort

    Secondary analysisRA

  24. Ann Rheum Dis

    Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres

    Randomized controlled trialRA

  25. Ann Rheum Dis

    Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials

    Meta-analysisVasculitis & PMR

  26. Ann Rheum Dis

    Specific descriptions of axial involvement are associated with radiographic damage development after 2 years in psoriatic arthritis patients

    Cohort studySpondyloarthritis & PsA

  27. Ann Rheum Dis

    Ultra-rare genetic variation in relapsing polychondritis: a whole-exome sequencing study

    Case-control studyAutoinflammatory & rare

  28. Ann Rheum Dis

    Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated querying

    Cohort studyVasculitis & PMR

  29. Ann Rheum Dis

    Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis

    Meta-analysisRA

  30. Ann Rheum Dis

    EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

    Guideline or statementVasculitis & PMR

  31. Ann Rheum Dis

    EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

    Guideline or statementLupus & APS

  32. Ann Rheum Dis

    Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis

    Mechanistic studySjögren's & overlap

  33. Ann Rheum Dis

    Global, regional and national temporal trends in prevalence for musculoskeletal disorders in women of childbearing age, 1990–2019: an age-period-cohort analysis based on the Global Burden of Disease Study 2019

    Cohort studyFibromyalgia & pain

  34. Ann Rheum Dis

    Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?

    Meta-analysisRA

  35. Ann Rheum Dis

    Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study

    Secondary analysisVasculitis & PMR

  36. Ann Rheum Dis

    Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica

    Guideline or statementVasculitis & PMR

  37. Ann Rheum Dis

    Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink

    Cohort studyGout & crystals

  38. Ann Rheum Dis

    Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study

    Cohort studyVasculitis & PMR

  39. Ann Rheum Dis

    Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

    Randomized controlled trialRA

  40. Ann Rheum Dis

    Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

    Randomized controlled trialRA

All 596 Briefs in ExploreShowing Briefs 441–480 of 596, newest first